


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



in which

each of A,B,D and E is independently C-R¹;

X is carbon;

Y is N;

Z is oxygen, sulphur, a C₁₋₆alkylene chain or a bond;

R¹ is independently selected from hydrogen, halogen, CN, nitro, S(O)_xR⁶, OR⁶, SO₂NR⁴R⁵, CONR⁴R⁵, NR⁴R⁵, NR⁷SO₂R⁷, NR⁷C(O)_xR⁷, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁₋₆alkyl, and aryl,

the latter four groups being optionally substituted by one or more substituents independently selected from 1-3 halogen atoms, $-OR^7$ and $-NR^4R^5$, $S(O)_xR^8$, $C(O)NR^4R^5$, where x is 0, 1 or 2;

R^3 is a quinoline group, which is optionally substituted by one or more substituents independently selected from halogen, CN, nitro, $S(O)_xR^6$, OR^7 , $SO_2NR^4R^5$, $CONR^4R^5$, NR^4R^5 , $NR^7SO_2R^3$, $NR^7C(O)_xR^6$, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_{1-6} alkyl, the latter three groups being optionally substituted by one or more substituents independently selected from halogen atoms, $-OR^6$ and $-NR^4R^5$, where x= 0, 1 or 2;

R^4 and R^5 independently represent a hydrogen atom, a C_{1-6} alkyl group, or aryl group the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, aryl, $-OR^{12}$ and $-NR^{13}R^{14}$, $-CONR^{13}R^{14}$, $-NR^{13}COR^{14}$, $-SO_2NR^{13}R^{14}$, $NR^{13}SO_2R^{14}$;

R^6 represents a C_{1-6} alkyl which may be optionally substituted by one or more substituents independently selected from halogen atoms, aryl, $-OR^9$ and $-NR^{10}R^{11}$;

each of R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , independently represents a hydrogen atom, C_1-C_6 , alkyl, or an aryl ~~or a heteroaryl~~ group which may be optionally substituted by one or more halogen atoms, OH, $O-C_1-C_6$ alkyl; and

R^{15} is hydrogen, C_{1-4} alkyl, $-COC_1-C_4$ alkyl, $-COQC_1-C_4$ alkyl, $Q=O$ or NR^6 .

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Previously Presented) A compound according to claim 1 in which Z is a bond.
6. (Cancelled)
7. (Cancelled)
8. (Previously Presented) A compound according to claim 1 in which Z is sulfur, methylene or a bond.
9. (Currently Amended) A compound according to claim 1 selected from:
5-methyl-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;
5-cyano-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;
3-(6-fluoro-4-quinolinyl)-4-(trifluoromethyl)-1*H*-indazole-1-acetic acid; and
4-iodo-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;
or a and pharmaceutically acceptable salt salts thereof.
10. (Cancelled)
11. (Withdrawn) A method of treating a disease mediated by prostaglandin D2, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt as defined in claim 1.
12. (Withdrawn) A method of treating according to claim 11 wherein the disease is asthma or rhinitis.
13. (Cancelled)

14. (Cancelled)

15. (Withdrawn-amended) The method according to claim 11 wherein the compound is selected from:

5-methyl-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;

5-cyano-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;

3-(6-fluoro-4-quinolinyl)-4-(trifluoromethyl)-1*H*-indazole-1-acetic acid; and

4-iodo-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;

or a and pharmaceutically acceptable salt salts thereof.